Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255037 | 0.88 | NOTUM (0.50) | ALDH1A1MEN1KMT2ANOTUMSIGMAR1 | |
| SCHEMBL15445286 | 0.86 | NOTUM (0.45) | ALDH1A1MEN1KMT2ANOTUMSIGMAR1 | |
| SCHEMBL24721143 | 0.85 | NPSR1 (0.45) | ALDH1A1MEN1KMT2ANOTUMSIGMAR1 | |
| SCHEMBL24721029 | 0.85 | NPSR1 (0.45) | ALDH1A1MEN1KMT2ANOTUMSIGMAR1 | |
| SCHEMBL24721104 | 0.85 | NPSR1 (0.45) | ALDH1A1MEN1KMT2ANOTUMSIGMAR1 | |
| SCHEMBL6262183 | 0.84 | SLC6A2 (0.52) | ALDH1A1MEN1USP2CDK4ALOX15 | |
| SCHEMBL21085252 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MEN1USP2CDK4ALOX15 | |
| SCHEMBL14060360 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MEN1USP2CDK4ALOX15 | |
| SCHEMBL16600454 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MEN1USP2CDK4ALOX15 | |
| SCHEMBL11852260 | 0.84 | GAA (0.47) | ALDH1A1MEN1USP2CDK4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 515 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1907253-A | Composition comprising amino heterocyclic compound for hair dyeing and dyeing method | SU JIANHUA (CN) | 2007-02-07 | — | — | CN | claimed |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-7078567-B2 | Amination process | JOHNSTON JEFFREY N | 2006-07-18 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| WO-2006009886-A1 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
| WO-2005113581-A1 | SUBSTITUTED PROLINES AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20040082778-A1 | Amination process | JOHNSTON JEFFREY N (US) | 2004-04-29 | — | — | US | disclosed |
| US-6670479-B2 | An sp2 hybridized radical is reacted with an azomethine group to form pyrrolidine and indole compounds | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20020128490-A1 | Amination process | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | ALDH1A1 1804/4885MEN1 2268/4885USP2 32/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | ALDH1A1 1173/4885MEN1 4405/4885USP2 4133/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ALDH1A1 4236/4885MEN1 1514/4885USP2 1956/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | ALDH1A1 2230/4885MEN1 2085/4885USP2 1076/4885 |
| US-20040082778-A1 | Amination process | IDO2, INMT, IDO1 | ALDH1A1 567/4885MEN1 3352/4885USP2 2957/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 3472/4885MEN1 4729/4885USP2 1932/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | ALDH1A1 2811/4885MEN1 2329/4885USP2 3818/4885 |
| US-20020128490-A1 | Amination process | IDO2, INMT, IDO1 | ALDH1A1 106/4885MEN1 3827/4885USP2 3472/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | ALDH1A1 2260/4885MEN1 4670/4885USP2 3735/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | ALDH1A1 1369/4885MEN1 1618/4885USP2 2862/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | ALDH1A1 2267/4885MEN1 2331/4885USP2 343/4885 |
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | ALDH1A1 3292/4885MEN1 1394/4885USP2 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.